Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Kenji Yamauchi, Tomoki Inaba, Hugh Shunsuke Colvin, Ichiro Sakakihara, Kumiko Yamamoto, Koichi Izumikawa, Sakuma Takahashi, Shigetomi Tanaka, Shigenao Ishikawa, Masaki Wato, Midori Ando & Masato Waki. (2022) Dasatinib-induced colitis: clinical, endoscopic and histological findings. Scandinavian Journal of Gastroenterology 57:4, pages 449-456.
Read now
Read now
Juan Luis Steegmann, Francisco Cervantes, Philipp le Coutre, Kimmo Porkka & Giuseppe Saglio. (2012) Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leukemia & Lymphoma 53:12, pages 2351-2361.
Read now
Read now
Gilhen H. Rodriguez, Saud I. Ahmed, Fadi Al-akhrass, Vijayashri Rallapalli & Amar Safdar. (2012) Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications. Leukemia & Lymphoma 53:8, pages 1530-1535.
Read now
Read now
Harrys A. Torres & Roy F. Chemaly. (2007) Viral infection or reactivation in patients during treatment with dasatinib: A call for screening?. Leukemia & Lymphoma 48:12, pages 2308-2309.
Read now
Read now
Articles from other publishers (15)
Süreyya YİĞİT KAYA. (2023) Recurrent Herpes Infection in Two Cases with Chronic Myeloid Leukemia Using DasatinibDasatinib Kullanan Kronik Myeloid Lösemi Tanılı İki Olguda Tekrarlayan Herpes Enfeksiyonu. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi 10:1, pages 65-66.
Crossref
Crossref
Hiroto Arino, Naokazu Muramae, Mitsumasa Okano, Kenta Mori, Kazunori Otsui & Kazuhiko Sakaguchi. (2022) Acute Onset of Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Two Weeks After COVID-19 Vaccination With mRNA-1273 With Possible Activation of Parvovirus B19: A Case Report With Literature Review. Cureus.
Crossref
Crossref
Rocío Seoane, Santiago Vidal, Yanis Hichem Bouzaher, Ahmed El Motiam & Carmen Rivas. (2020) The Interaction of Viruses with the Cellular Senescence Response. Biology 9:12, pages 455.
Crossref
Crossref
Jorge Labrador, Gerardo J. Hermida, Rodolfo Alvarez, Victor Anso, Pilar de Vicente, Mercedes Goñi & Tomas Jose Gonzalez-Lopez. (2020) Dasatinib and FLAG-IDA Is an Effective Therapy for Initial Myeloid Blast Crisis but Involves a High Risk of Opportunistic Infections. Case Reports in Hematology 2020, pages 1-4.
Crossref
Crossref
Da Jung Kim, Seri Jeong, Seom Gim Kong & Ho Sup Lee. (2019) First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia. BLOOD RESEARCH 54:2, pages 151-153.
Crossref
Crossref
M. Reinwald, J.T. Silva, N.J. Mueller, J. Fortún, C. Garzoni, J.W. de Fijter, M. Fernández-Ruiz, P. Grossi & J.M. Aguado. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clinical Microbiology and Infection 24, pages S53-S70.
Crossref
Crossref
Daniel P. Prestes, Esther Arbona, Alexandra Nevett-Fernandez, Ann E. Woolley, Vincent T. Ho, Sophia Koo, Lindsey R. Baden, John Koreth, Sarah P. Hammond, Nicolas C. Issa & Francisco M. Marty. (2017) Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation. Clinical Infectious Diseases 65:3, pages 510-513.
Crossref
Crossref
Morten P. Oksvold, Johanna M. Duyvestyn, Samantha A. Dagger, Samuel J. Taylor, Lise Forfang, June H. Myklebust, Erlend B. Smeland & Wallace Y. Langdon. (2015) The targeting of human and mouse B lymphocytes by dasatinib. Experimental Hematology 43:5, pages 352-363.e4.
Crossref
Crossref
Mark ReinwaldTobias BochWolf-Karsten HofmannDieter Buchheidt. (2016) Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights 10s3, pages BMI.S22430.
Crossref
Crossref
Hisashi Takei, Takeki Mitsui, Naru Sato, Akio Saito, Takumi Hoshino, Hiromi Koiso, Makiko Takizawa, Akihiko Yokohama, Takayuki Saito, Norifumi Tsukamoto, Kazuhiro Murakami, Hiroshi Handa & Yoshihisa Nojima. (2014) A Newly Diagnosed CML-CP HBV Carrier was Safely Treated with Dasatinib and Entecavir. The Kitakanto Medical Journal 64:1, pages 51-55.
Crossref
Crossref
Hugues de LavalladeAhmad KhoderMelanie HartAnushruti SarvariaTakuya SekineAbdullah AlsulimanStephan Mielke, Alexandra BazeosKate StringarisSara AliDragana MilojkovicLetizia ForoniAristeidis ChaidosNichola CooperIan GabrielJane ApperleySarah Belsey, Robert J. Flanagan, John GoldmanElizabeth J. ShpallPeter KelleherDavid MarinKatayoun Rezvani. (2013) Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood 122:2, pages 227-238.
Crossref
Crossref
Marcio Nucci, Nair Bijay & Elias Anaissie. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy
392
410
.
Moritaka Gotoh, Tetsuzo Tauchi, Seiichiro Yoshizawa, Toshihiko Kitahara, Toru Kiguchi, Yukihiko Kimura & Kazuma Ohyashiki. (2010) Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR–ABL mutation. International Journal of Hematology 91:1, pages 128-131.
Crossref
Crossref
Cara K. Fraser, Erin L. Lousberg, Raman Kumar, Timothy P. Hughes, Kerrilyn R. Diener & John D. Hayball. (2009) Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo. Experimental Hematology 37:12, pages 1435-1444.
Crossref
Crossref
Cara K. Fraser, Stephen J. Blake, Kerrilyn R. Diener, A. Bruce Lyons, Michael P. Brown, Timothy P. Hughes & John D. Hayball. (2009) Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Experimental Hematology 37:2, pages 256-265.
Crossref
Crossref